Alnylam Pharmaceuticals (ALNY)

Executive Summary

Alnylam Pharmaceuticals is the leading RNA interference (RNAi) therapeutics company, with four FDA-approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and a robust pipeline targeting rare and prevalent diseases. The company's platform enables gene silencing at the mRNA level, offering a transformative approach for conditions with high unmet need. In 2025, Alnylam reported strong commercial execution, with Amvuttra (vutrisiran) capturing significant share in the hereditary transthyretin amyloidosis market. The pipeline includes ALN-AGT01 for hypertension (Phase 2 completed), ALN-BCAT for hepatocellular carcinoma (Phase 1), and ALN-4285 for an undisclosed indication (Phase 1). The company is also advancing next-generation GalNAc conjugates and exploring central nervous system delivery. With a cash-rich balance sheet and expanding royalty partnerships, Alnylam is well-positioned for sustained growth, though it faces competition from newer modalities and pricing pressures. The conviction score of 82 reflects its validated platform, commercial traction, and upcoming catalysts, balanced by pipeline risk and market dynamics.

Upcoming Catalysts (preview)

• Q4 2026Amvuttra (vutrisiran) US label expansion to include cardiomyopathy75% success
• Q2 2026ALN-AGT01 Phase 2 hypertension data and Phase 3 initiation70% success
• Q3 2026Phase 1 data for ALN-BCAT in hepatocellular carcinoma60% success